Micro and Nanoparticle Drug Delivery Systems for Preventing Allotransplant Rejection

Overview

Journal Clin Immunol

Specialty Allergy & Immunology

Date 2015 May 5

PMID 25937032

Citations 24

Authors

James D Fisher

Abhinav P Acharya

Steven R Little

Affiliations

Soon will be listed here.

Abstract

Despite decades of advances in transplant immunology, tissue damage caused by acute allograft rejection remains the primary cause of morbidity and mortality in the transplant recipient. Moreover, the long-term sequelae of lifelong immunosuppression leaves patients at risk for developing a host of other deleterious conditions. Controlled drug delivery using micro- and nanoparticles (MNPs) is an effective way to deliver higher local doses of a given drug to specific tissues and cells while mitigating systemic effects. Herein, we review several descriptions of MNP immunotherapies aimed at prolonging allograft survival. We also discuss developments in the field of biomimetic drug delivery that use MNP constructs to induce and recruit our bodies' own suppressive immune cells. Finally, we comment on the regulatory pathway associated with these drug delivery systems. Collectively, it is our hope the studies described in this review will help to usher in a new era of immunotherapy in organ transplantation.

Citing Articles

Local delivery of an adenosine receptor agonist reduces inflammation associated with contact hypersensitivity.

Bentley E, Subick S, Doran J, Kobyra J, Balmert S, Little S Drug Deliv Transl Res. 2025; .

PMID: 40057627 DOI: 10.1007/s13346-025-01831-x.

Nanoparticle-based T cell immunoimaging and immunomodulatory for diagnosing and treating transplant rejection.

Ding M, Gao T, Song Y, Yi L, Li W, Deng C Heliyon. 2024; 10(2):e24203.

PMID: 38312645 PMC: 10835187. DOI: 10.1016/j.heliyon.2024.e24203.

Bioengineered particles expand myelin-specific regulatory T cells and reverse autoreactivity in a mouse model of multiple sclerosis.

Rhodes K, Tzeng S, Iglesias M, Lee D, Storm K, Neshat S Sci Adv. 2023; 9(22):eadd8693.

PMID: 37267370 PMC: 10413683. DOI: 10.1126/sciadv.add8693.

Latest advances in biomimetic nanomaterials for diagnosis and treatment of cardiovascular disease.

Gong Y, Liu H, Ke S, Zhuo L, Wang H Front Cardiovasc Med. 2023; 9:1037741.

PMID: 36684578 PMC: 9846151. DOI: 10.3389/fcvm.2022.1037741.

Short term, low dose alpha-ketoglutarate based polymeric nanoparticles with methotrexate reverse rheumatoid arthritis symptoms in mice and modulate T helper cell responses.

Mangal J, Inamdar S, Suresh A, Jaggarapu M, Esrafili A, Ng N Biomater Sci. 2022; 10(23):6688-6697.

PMID: 36190458 PMC: 9691612. DOI: 10.1039/d2bm00415a.

References

Kino T, Hatanaka H, Hashimoto M, Nishiyama M, Goto T, OKUHARA M . FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo). 1987; 40(9):1249-55. DOI: 10.7164/antibiotics.40.1249. View

Praveen G, Sreerekha P, Menon D, Nair S, Chennazhi K . Fibrin nanoconstructs: a novel processing method and their use as controlled delivery agents. Nanotechnology. 2012; 23(9):095102. DOI: 10.1088/0957-4484/23/9/095102. View

Lamprecht A, Yamamoto H, Takeuchi H, Kawashima Y . Nanoparticles enhance therapeutic efficiency by selectively increased local drug dose in experimental colitis in rats. J Pharmacol Exp Ther. 2005; 315(1):196-202. DOI: 10.1124/jpet.105.088146. View

Italia J, Bhardwaj V, Kumar M . Disease, destination, dose and delivery aspects of ciclosporin: the state of the art. Drug Discov Today. 2006; 11(17-18):846-54. DOI: 10.1016/j.drudis.2006.07.015. View

Lee I, Wang L, Wells A, Dorf M, Ozkaynak E, Hancock W . Recruitment of Foxp3+ T regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor. J Exp Med. 2005; 201(7):1037-44. PMC: 2213137. DOI: 10.1084/jem.20041709. View

Yoshikawa H, Seebach S . Lymphotropic delivery of cyclosporin A by intramuscular injection of biodegradable microspheres in mice. Biol Pharm Bull. 1996; 19(11):1527-9. DOI: 10.1248/bpb.19.1527. View

Wieckiewicz J, Goto R, Wood K . T regulatory cells and the control of alloimmunity: from characterisation to clinical application. Curr Opin Immunol. 2010; 22(5):662-8. PMC: 3025322. DOI: 10.1016/j.coi.2010.08.011. View

Naesens M, Kuypers D, Sarwal M . Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009; 4(2):481-508. DOI: 10.2215/CJN.04800908. View

Warty V, Diven W, Cadoff E, Todo S, Starzl T, Sanghvi A . FK506: a novel immunosuppressive agent. Characteristics of binding and uptake by human lymphocytes. Transplantation. 1988; 46(3):453-5. PMC: 2954623. DOI: 10.1097/00007890-198809000-00025. View

10.

Hackstein H, Taner T, Zahorchak A, Morelli A, Logar A, Gessner A . Rapamycin inhibits IL-4--induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood. 2003; 101(11):4457-63. DOI: 10.1182/blood-2002-11-3370. View

11.

Yuan X, Yuan Y, Jiang W, Liu J, Tian E, Shun H . Preparation of rapamycin-loaded chitosan/PLA nanoparticles for immunosuppression in corneal transplantation. Int J Pharm. 2007; 349(1-2):241-8. DOI: 10.1016/j.ijpharm.2007.07.045. View

12.

Battaglia M, Stabilini A, Draghici E, Gregori S, Mocchetti C, Bonifacio E . Rapamycin and interleukin-10 treatment induces T regulatory type 1 cells that mediate antigen-specific transplantation tolerance. Diabetes. 2005; 55(1):40-9. View

13.

Jhunjhunwala S, Balmert S, Raimondi G, Dons E, Nichols E, Thomson A . Controlled release formulations of IL-2, TGF-β1 and rapamycin for the induction of regulatory T cells. J Control Release. 2012; 159(1):78-84. PMC: 3706997. DOI: 10.1016/j.jconrel.2012.01.013. View

14.

Zhang Y, Chan H, Leong K . Advanced materials and processing for drug delivery: the past and the future. Adv Drug Deliv Rev. 2012; 65(1):104-20. PMC: 3565095. DOI: 10.1016/j.addr.2012.10.003. View

15.

Singha K, Namgung R, Kim W . Polymers in small-interfering RNA delivery. Nucleic Acid Ther. 2011; 21(3):133-47. PMC: 3198620. DOI: 10.1089/nat.2011.0293. View

16.

Black K, Hewitt C, FRASER L, Osborne J, Achauer B, Martin D . Cosmas and Damian in the laboratory. N Engl J Med. 1982; 306(6):368-9. DOI: 10.1056/NEJM198202113060620. View

17.

Knight S, Russell N, Barcena L, Morris P . Mycophenolate mofetil decreases acute rejection and may improve graft survival in renal transplant recipients when compared with azathioprine: a systematic review. Transplantation. 2009; 87(6):785-94. DOI: 10.1097/TP.0b013e3181952623. View

18.

Gao W, Thompson L, Zhou Q, Putheti P, Fahmy T, Strom T . Treg versus Th17 lymphocyte lineages are cross-regulated by LIF versus IL-6. Cell Cycle. 2009; 8(9):1444-50. PMC: 2881570. DOI: 10.4161/cc.8.9.8348. View

19.

Labowsky M, Fahmy T . Diffusive transfer between two intensely interacting cells with limited surface kinetics. Chem Eng Sci. 2012; 74:114-123. PMC: 3319135. DOI: 10.1016/j.ces.2012.02.001. View

20.

Champion J, Walker A, Mitragotri S . Role of particle size in phagocytosis of polymeric microspheres. Pharm Res. 2008; 25(8):1815-21. PMC: 2793372. DOI: 10.1007/s11095-008-9562-y. View